Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Valdecoxib regulatory update

PFE issued a "dear healthcare professional" letter warning that patients taking COX-2 inhibitor Bextra valdcoxib were at greater risk

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE